FLT3 and acute myeloid leukemia: Venetoclax, with a mechanism B cell lymphoma-2 (BCL-2) inhibition, ivosidenib and enasidenib inhibiting isocitrate dehydrogenase activity, glasdegib that inhibits the hedgehog pathway, and Fms-like tyrosine kinase 3 (FLT3) inhibitors are new agents for the treatment of a subset of AML [3].